Dave Williamson, CIO of Abzena, discusses AI, data strategy and how the company stays ahead in biotech, driving impactful solutions for clients
ABZENA
Dave Williamson, CIO of Abzena, discusses AI, data strategy and how the company stays ahead in biotech, driving impactful solutions for clients
There are plenty of ways pharmaceutical companies are working to accelerate the development process, with innovation and technology propelling discovery and driving impact.
Abzena is a leading end-to-end bioconjugate, ADC and complex biologics CDMO + CRO. From discovery through commercial launch, it supports customers with fully integrated programmes – as well as individual services – designed to de-risk and streamline the development of new treatments for patients in need. Research, development and cGMP happens across its global facilities – San Diego, California and Bristol, Pennsylvania in the US and Cambridge in the UK.
CIO Dave Williamson is at the forefront of Abzena’ s technological development, leveraging data that is critical to automation, drug discovery and accelerating outcomes.
A chemist by training, Dave’ s career began with a stint in the US Army, which paid for his university studies – an experience that allowed him to travel the world and“ go on many different adventures”.
He says:“ I’ ve always been fascinated by science, how things work.”
“ When you get really smart people together and they solve problems, they often solve in different ways”
DAVE WILLIAMSON, CIO, ABZENA
4 abzena. com